Natera Inc (NTRA)
Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell
$203.50
Buy
$204.50
$-0.50 (-0.25%)
Prices updated at 23 May 2026, 00:59 EDT
| Prices minimum 15 mins delay
Prices in USD
Natera Inc is a provider of diagnostic services predominantly in the United States. It offers various tests which detect chromosomal abnormalities, reasons for miscarriages and paternity.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Diagnostics & Research
Chairman
Dr. Matthew Rabinowitz
CEO
Mr. Steven Leonard Chapman
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
6,140
Head office
13011 McCallen Pass
Austin
United States
78753
Key personnel
Owner name | Salary |
|---|---|
Mr. Eric N. Rubino Director | - |
Mr. Herm Rosenman Independent Director | 0.03m |
Dr. James I. Healy, M.D.,PhD Independent Director | 0.02m |
Ms. Ruth Williams Brinkley Independent Director | - |
Mr. Roelof Frederik Botha Lead Independent Director | 0.03m |
Dr. Matthew Rabinowitz Executive Chairman of the Board | 0.43m |
Mr. Jonathan Sheena Director | - |
Dr. Roy D. Baynes, M.D.,PhD Independent Director | 0.02m |
Mr. Michael Brophy Chief Financial Officer and Principal Accounting Officer | 0.56m |
Dr. Gail B. Marcus Independent Director | 0.02m |
Mr. Steven Leonard Chapman Director, Chief Executive Officer and Co-President | 0.85m |
Dr. Monica Bertagnolli, M.D. Independent Director | 0.00m |
Dr. Rowan E. Chapman, PhD Independent Director | 0.02m |
Mr. Daniel Rabinowitz Secretary and Chief Legal Officer | - |
Mr. Solomon Moshkevich President, Clinical Diagnostics | 0.50m |
Mr. John Fesko Co-President and Chief Business Officer | 0.50m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| JPMorgan Chase & Co | 13,386,667 |
| Vanguard Group Inc | 12,306,424 |
| T. Rowe Price Associates, Inc. | 12,184,876 |
| BlackRock Inc | 10,859,441 |
| J.P. Morgan Investment Management, Inc. | 8,657,644 |
Director dealings
Date | Action |
|---|---|
| 19 Dec 2025 | - |
| 19 Dec 2025 | - |
| 19 Dec 2025 | - |
| 19 Dec 2025 | - |
| 15 Dec 2025 | - |
| 17 Dec 2025 | - |
| 17 Dec 2025 | - |
| 17 Dec 2025 | - |
| 12 Dec 2025 | - |
| 10 Dec 2025 | - |
| 15 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 09 Dec 2025 | - |
| 09 Dec 2025 | - |
| 05 Dec 2025 | - |
| 05 Dec 2025 | - |
| 05 Dec 2025 | - |
| 05 Dec 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
